Gene therapy shows promise against blood-clotting disease
By Marilynn Marchione,
Associated Press
| 12. 07. 2017
Gene therapy has freed 10 men from nearly all symptoms of hemophilia for a year so far, in a study that fuels hopes that a one-time treatment can give long-lasting help and perhaps even cure the blood disease.
Hemophilia almost always strikes males and is caused by lack of a gene that makes a protein needed for blood to clot. Small cuts or bruises can be life-threatening, and many people need treatments once or more a week to prevent serious bleeding.
The therapy supplies the missing gene, using a virus that’s been modified so it won’t cause illness but ferries the DNA instructions to liver cells, which use them to make the clotting factor. The treatment is given through an IV.
In a study published Wednesday by the New England Journal of Medicine, all 10 men given the therapy now make clotting factor in the normal range. Bleeding episodes were reduced from about one a month before gene therapy to less than one a year. Nine of the 10 no longer need clotting factor treatments, and the 10th needs far...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...